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PRS27
CliniCal and EConomiC BEnEfitS aSSoCiatEd With lESS USE of 
flUtiCaSonE in PEdiatRiC PatiEntS With PERSiStEnt aSthma tREatEd 
With high doSES of SPECifiC allERgEn immUnothERaPy to mitES
Polanco C
Merck, Madrid, Spain
Objectives: The existing guidelines recommend the minimum effective dose of 
inhaled corticosteroids in children with persistent asthma. Clinical studies and 
recent Cochrane reviews stablish the existence of a significant difference in the 
growth rate of pediatric patients that receive corticoids against those who do not 
receive them1-5. Another study showed that pediatric patients treated with sub-
cutaneous immunotherapy (IT) to house dust mites required a significant lower 
dose of fluticasone propionate (PF). Quantify the savings associated with the dose 
decrease of PF in pediatric patients with allergic asthma treated for three years 
with high dose specific-allergen immunotherapy to mites MethOds: The average 
reduction of PF comes from an observational, randomized, three years prospective 
study (N= 65; 33 treated with IT+FP). The number of containers per patient were 
calculated as well as its economical savings regarding the baseline situation. The 
immunotherapy used and the PF were accounted for by means of RRP. Results: 
The PF accumulated savings is equivalent to 29,3% of the immunotherapy phar-
macological costs. Since PF is a reduced contribution medication, the savings for 
the NHS are 44,9%-67,3% and 5,9%-3,9% for the patient depending on the income 
range. cOnclusiOns: Adding high dose specific-allergen immunotherapy to mites 
to pharmacological treatment retains control over the allergic asthma and reduces 
the use of corticoids, consequently minimizing the impact on the growth rate of 
the patients and generates economical savings.
PRS28
EConomiC analySiS of CoSt of dRUg tREatmEnt involvEd in thE 
maintainanCE thERaPy of CoPd
Hussain S, Kumari S
National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India
Objectives: To calculate the fluctuation in the drug cost involved in the treatment 
of Chronic Obstructive Pulmonary Disease (COPD) during 2013-2015. MethOds: 
Standard treatment guidelines (STG), 4th edition were perused to understand the 
management of COPD. Current Index of Medical Specialities (CIMS) Oct - Jan 2013, 
2014 and 2015 issue were used to capture the price of drugs. One day cost of treat-
ment and its variation was studied. Results: According to STG, drugs needed 
for the maintenance treatment of COPD includes Salbutamol inhaler 200mcg 4 
times a day or Terbutaline 250mcg inhaler, Ipratropium bromide 200mcg inhaler 
2 times a day, Theophylline 100mg tablets 3 times a day, Amoxicillin + Clavulanic 
acid (500mg + 125mg) injection 3 times a day, Fluticasone 100mcg inhalation once 
a day, Montelukast tablet 5mg once a day. The minimum and maximum difference 
in cost of one day maintenance was found to be 136%, 182% and 169% in the year 
2013, 2014 and 2015 respectively. This fluctuation was observed by totaling the price 
of all the drugs mentioned above. cOnclusiOns: Wide variation exists between 
the minimum and maximum cost of maintainance therapy of COPD. Government 
should take some step in order to regulate and to bring uniformity in price. So that it 
can be affordable by a common man which will ultimately improve the compliance 
and reduce the economic burden.
PRS29
to StUdy thE CliniCal ChaRaCtERiStiCS, tREatmEnt PattERn 
and faCtoRS aSSoCiatEd With thE total hoSPital CoSt in aCUtE 
RESPiRatoRy diStRESS SyndRomE in tERtiaRy CaRE hoSPital
Sharma A1, Thunga G2, Guddattu V2
1Manipal University, manipal, India, 2Manipal College of Pharmaceutical Sciences, Manipal 
University, Manipal, India
Objectives: To analyze the clinical symptoms, treatment pattern, outcomes and 
factors associated with total cost of treatment. MethOds: A retrospective cross 
sectional study was conducted in tertiary care hospital. The patient details such as 
demographical data, clinical features, treatment and outcome were collected from 
the Medical Records Department. The total cost of treatment was collected from 
Finance Department. Data were analyzed by using SPSS 20.0 Results: Mean age of 
the study population was found to be 42.7±18.2 year with majority of male 94(52.2%). 
Sepsis (59(32.8%)) was the most common etiology for ARDS in our study population. 
Analysis of 180 cases showed that total number of hospitalization days were 1793 
and total cost of treatment was 11,005,448 INR. The patients who received corticos-
teroid therapy before 48 hours had better recovery rate. Mean ventilation days in the 
group of patients who received early glucocorticoid therapy were less (9.29±6.06) 
then those who received late therapy (13.64±6.03) cOnclusiOns: Mortality rate 
associated with ARDS was relatively high. Management with steroids has no special 
benefit in reduction in mortality rate. Time of start of steroid therapy plays an impor-
tant role in the management and was observed that early start of steroid therapy 
showed better recovery rate as well as reduction in hospitalization and ventilation 
days. The total treatment cost for the management of ARDS is relatively high.
PRS30
PUlmonaRy aRtERial hyPERtEnSion (Pah): REal-WoRld tREatmEnt 
PattERnS, oUtComES and CoStS BaSEd on WoRld hEalth oRganization 
(Who) fUnCtional ClaSS (fC)
Dufour R1, Pruett J2, Lane D1, Hu N1, Stemkowski S1, Raspa S2, Drake W2
1Comprehensive Health Insights, Louisville, KY, USA, 2Actelion Pharmaceuticals, Inc., South San 
Francisco, CA, USA
Objectives: Retrospective database studies of PAH using US payer claims data 
have limitations due to lack of specific ICD-9 codes for PAH and ability to identify 
patient severity. A previous study validated an algorithm including patients with 
non-specific PH codes and a claim for an advanced PAH drug therapy. This study used 
provider-reported disease severity – FC – to examine the impact of FC on healthcare 
Objectives: Knowing the burden of community-acquired pneumonia (CAP) 
is important for taking preventive measures. This study aimed to calculate 
the direct costs of CAP in adults > 18 years old. MethOds: Data of outpatients 
and inpatients with CAP from 18-month period were retrospectively evaluated. 
Numbers of radiological and laboratory analyses, hospital stay (day), and spe-
cialist visits were multiplied by the relevant unit costs and the cost per patient 
was calculated. Total drug costs were calculated by multiplying daily drug cost 
with medication day for each drug for inpatients and by based on packet price 
of each drug for outpatients. Costs were expressed as median (minimum-max-
imum). Results: The mean ages were 61.56±17.87 years in inpatients (n= 208, 
51.4% males) and, 53.78±17.46 years in outpatients (n= 211, 53.6% males). The 
ratios of being ≥ 65 years old in inpatients and outpatients were 48.6% and 28.9%, 
respectively. Among inpatients, 36.5% had chronic obstructive pulmonary disease 
(COPD) and18.3% had hypertension. Among outpatients, 22.7% had COPD and 
20.4% had asthma. The total cost was 300.01€ (75.11€ -9,870.16€ ) for inpatients 
and 39.43€ (5.34€ -230.34€ ) for outpatients. Drug cost had the highest share of 
total cost both in inpatients and outpatients. In inpatients, total cost was 345.21€ 
(75.11€ -9,870.16€ ) in those ≥ 65 years old and 283.35€ (79.13€ -3,785.71€ ) in those 
< 65 years old (p= 0.014); this difference was not found in outpatients. The total 
cost was 633.73€ (313.11€ -4,375.23€ ) in inpatients hospitalized more than once and 
270.67€ (75.11€ -9,870.16€ ) in those hospitalized once (p< 0.001). In inpatients with 
and without comorbidities, total costs were 308.14€ (75.11€ -9,870.16€ ) and 221.08€ 
(92.20€ -3785.71€ ), respectively (p= 0.016). In outpatients with and without comor-
bidities, total costs were 44.97€ (5.34€ -230.34€ ) and 26.56€ (5.34€ -110.96€ ), respec-
tively (p< 0.001). cOnclusiOns: Costs were higher in patients with advanced 
age, having comorbidity, and hospitalized more than once. For decreasing the 
economic burden of CAP on healthcare system, preventive measures should be 
taken.
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thE aSSoCiation BEtWEEn Smoking CESSation oUtPatiEnt viSitS and 
total mEdiCal CoStS: an analySiS of JaPanESE EmPloyEE BaSEd PUBliC 
hEalth inSURanCE data
Suwa K1, Nakamura Y2, Yoshikawa R1, Gunji T2, Iwasaki K2, Igarashi A3
1Pfizer Japan Inc., Tokyo, Japan, 2Milliman, Tokyo, Japan, 3University of Tokyo, Graduate School of 
Pharmaceutical Sciences, Tokyo, Japan
Objectives: The purpose of this study was to estimate short-term medical cost 
savings, including costs not directly associated with Smoking Cessation Outpatient 
Visits (SCOVs), from claims data of employee based public health insurance in 
Japan. MethOds: We conducted two analyses using claims data from January 
2005 to December 2013 provided by Japan Medical Data Center Co., Ltd. In the 
first analysis, we compared medical costs composed of inpatient, outpatient, and 
medications of the SCOV group, smokers having SCOVs, with those of non-SCOV 
group for each year. The first day of index year 0 is the day of first SCOV for the 
SCOV group and is the day after one observation year for the non-SCOV group. 
In the second analysis, among smokers with SCOVs, a mean increase ratio of 
medical costs was calculated, varying by the number of SCOVs. Results: In the 
first analysis, medical costs per patient per years (PPPYs) of the SCOV group were 
¥95,200 at year -1, ¥173,400 at year 0, ¥130,900 at year 1 and ¥116,100 at year 5, and 
PPPYs of non-SCOV group were ¥95,200 at year -1, ¥100,700 at year 0, ¥108,100 at 
year 1 and ¥125,900 at year 5. The PPPY of SCOV group at year 0 was higher than 
that of non-SCOV group at year 0 but the relation was reversed at year 5. In the 
second analysis, the mean increase ratio of medical costs of the one-SCOV group 
was the highest, 58%, and that of five-SCOV group was the smallest, 34%. This 
measure showed a downward trend. cOnclusiOns: Results are suggestive of 
a possibility that the future medical costs of patients with smoking cessation 
outpatient visits are lower than those without smoking cessation outpatient visit 
and increasing the number of smoking cessation outpatient visits decreases the 
mean increase ratios of medical costs.
PRS26
CoSt ConSEqUEnCE of PREvEntivE tREatmEnt With om 85 BaCtERial 
lySatE ComPaREd to thE SamE PatiEntS WithoUt om 85 thE PREvioUS 
yEaR in allERgiC RhinitiS, aSthma and CoPd in aRgEntina
Koatz AM1, Zakin L2, Ciceran A3
1Facultad de Medicina - Universidad de Buenos Aires, Buenos Aires, Argentina, 2Axelys santé, 
Paris, France, 3Universidad de Buenos Aires, Buenos Aires, Argentina
Objectives: To evaluate the cost efficiency of preventive treatment with OM 85 in 
patients with AR, asthma and COPD compared to the same patients the previous 
year only receiving standard of care. MethOds: This multi-centre, clinical trial was 
conducted in Argentina in 2010. Eighty-four patients with COPD, allergic rhinitis 
(AR) and asthma aged 16-65 years who had not received a bacterial lysate in 2009 
were included. In 2010, the same patients received OM-85 bacterial lysate capsule. 
Capsules were administered daily for 10 consecutive days per month for a duration 
of 3 consecutive months. Results: the number of reinfections and exacerbations 
in the OM 85 arm was decreased from 85% to 45.5% (p< 0.05) and from 65.7% to 
34.9% (p< 0.05) vs the previous year, respectively. Hospitalizations were 2% in the 
OM 85 group and 12% for the previous year. The average total cost per patient per 
month with AR caused by reinfections and exacerbations was 448.9 ARS and 269.9 
ARS in the OM 85 arm compared to 660.40 ARS and 574.40 ARS in the previous year. 
In patients with asthma total cost for reinfections and exacerbations was 487.9 ARS 
and 473.9 ARS in the OM 85 arm compared to 1’144 ARS and 970 ARS in the previ-
ous year. Reinfections and exacerbations total cost in COPD patients was 1356.5 
ARS and 1217.5 ARS in the OM 85 patients but amounted to 1’708.2 ARS and 1599.6 
ARS, respectively, in the previous year. cOnclusiOns: Preventive treatment with 
OM 85 in patients with allergic rhinitis, asthma and COPD significantly reduces 
reinfections rates, exacerbations and hospitalizations compared to the previous 
year. Associated cost savings have been substantial and ranged from 15% to 60% vs 
previous year (no prophylaxis).
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1Sunnybrook Research Institute, Toronto, ON, Canada, 2St. Michael’s Hospital, Toronto, ON, 
Canada, 3Boehringer-Ingelheim, Burlington, ON, Canada
Objectives: To collect health care resource utilization (HCRU) in the management 
of idiopathic pulmonary fibrosis (IPF) patients. MethOds: A retrospective, longi-
tudinal, cohort study design via chart review analysis of anonymized IPF patient 
records is being conducted in order to collect healthcare resource data from a major 
IPF treatment centre in Ontario, Canada. A convenience sample of 90 IPF patients 
was selected with inclusion criteria of adult age at diagnosis having a confirmed 
diagnosis of IPF, and minimum of one respirologist visit. Demographics and HCRU 
data were collected with descriptive statistics to be presented. Costs are presented 
in 2014 Canadian dollars. Results: For the preliminary analysis, 45 IPF patients 
met the study inclusion criteria. 30 were male with the mean age at diagnosis 
being 71.3 years (range 39-89 years). Information about IPF treatments, supportive 
medications, tests/procedures, physician visits and hospitalizations were obtained 
from the charts. The overall cost of the cohort was $873,936, with a mean cost per 
patient of $19,421 ($986-$117,004, ±$18,961). The 30 day cost per patient was $337. 
IPF treatments accounted for more than half the total cost ($494,416). Patients were 
stratified by disease severity at diagnosis and followed over progression. 33 were 
diagnosed as initially having mild disease, and 12 had moderate disease. Patients 
with mild disease were followed an average of 65.8 months and had an average 
per patient cost of $20,029 (30 day cost: $305). Moderate patients were followed 
an average of 35.0 months and had an average per patient cost of $17,747 (30 day 
cost: $592). cOnclusiOns: Preliminary results from a major IPF treatment centre 
indicate substantial HCRU associated with IPF management. The authors plan to 
complete data extraction at the centre in order to determine HCRU and cost results 
for the full cohort.
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CliniCal and EConomiC BURdEn of aSthma and ChRoniC oBStRUCtivE 
PUlmonaRy diSEaSE (CoPd) in Poland: EStimatEd imPaCt of PooR 
inhalation tEChniqUE With inhalEd CoRtiCoStERoid and long-
aCting BEta agoniSt fixEd-doSE ComBinationS
Bijos P1, Kaczynski J1, Torvinen S2, Lenarczyk E3, Wrona W3, Plich A2, Lewis A4,  
Blackney M4
1Teva Pharmaceuticals Polska, Warszawa, Poland, 2Teva Pharmaceuticals Europe B.V., 
Amsterdam, The Netherlands, 3HealthQuest, Warszawa, Poland, 4Covance Market Access, London, 
UK
Objectives: Fixed-dose combinations (FDCs) of inhaled corticosteroids (ICS) and 
long-acting beta agonists (LABA) are recommended in moderate to severe persis-
tent asthma and chronic obstructive pulmonary disease (COPD). The aim of the 
analysis was to evaluate the clinical and economic burden of asthma and COPD in 
Poland, and assess the impact of poor inhalation technique with ICS + LABA FDCs 
- which is common with inhalers - reimbursed in Poland on costs and resource 
use. MethOds: The eligible patient population was estimated based on Polish 
asthma and COPD prevalence rates, with the proportion of patients receiving FDCs 
based on available National Health Fund (NHF) data. Costs of inhalers, scheduled 
and unscheduled health care events were taken from publicly available sources. The 
analysis was conducted in one-year horizon from the payer and patient perspective 
(direct costs) and societal perspective (indirect costs). Frequency of poor inhalation 
technique (occurrence of critical inhaler errors) and the associated increased risk 
of unscheduled health care events were estimated based on a large (N = 1,664), 
cross-sectional, observational study, performed in Italy in 2008. Results: In Poland 
207,801 adults with asthma and COPD receive an ICS + LABA FDCs annually, of which 
56,937 are estimated to have poor inhalation technique. Total direct costs were 
estimated to be 378 million PLN (91.1 million EUR)and productivity loss costs – 20.4 
million PLN (4.9 million EUR) cOnclusiOns: The clinical and economic burden 
of asthma and COPD is considerable in Poland and poor inhalation technique is a 
substantial contributor to costs of unscheduled healthcare events. Novel inhalers 
with easier inhalation technique may offer clinical and economic benefits in the 
management of asthma and COPD.
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nEW CoPd mEdiCinal PRodUCtS EntRanCE analySiS and thEiR 
inflUEnCE on thE nUmBER and CoSt of hoSPitalizatonS dUE to CoPd 
ExaCERBationS
Dimitrova M1, Kamusheva M1, Mitov K1, Petkova V1, Dimitrov J2, Petrova G1
1Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria, 2University Hospital for 
specialized treatment of pulmonary diseases, Sofia, Bulgaria
Objectives: To perform an analysis of the changes in the number and cost of hospi-
talizations of COPD patients after the introduction of the new inhalation medicines 
into the Positive drug list (PDL). MethOds: It is retrospective, real life observational 
study on the hospitalizations of COPD patients due to exacerbations and the inclusion 
of new medicinal products for the treatment of COPD in PDL for a 6-year period (2009-
2014). Data for the number of hospitalizations due to COPD exacerbations, their cost, 
and the number of COPD patients with valid health insurance status was collected 
from National Health Insurance Fund (NHIF). Newly entered medicinal products for 
COPD were extracted from the PDL. Macro-costing approach was applied to evalu-
ate the total medical costs on hospitalizations. Statistical processing was through 
Spearman and Pearson correlation, and Freedman test. Results: Before 2009 COPD 
pharmacotherapy was partially reimbursed by NHIF. ICS/LABA were included with 
100% reimbursement and LAMA with 75% in PDL in 2010. In 2013 and 2014 in PDL 
were included glycopyrronim, aclidinium and indacaterol/glycopyrronium with 75% 
reimbursement and two generic ICS/LABA with 100% reimbursement. A statistically 
significant decrease in the hospitalizations due to COPD exacerbations was observed 
– from 28% in 2009 to 19% in 2014 (p< 0.0001). On the other hand, there is an increase 
in the total cost of hospitalizations mostly due to the increase in the cost of hospital 
services. Statistically significant correlation with linear nature exists also between 
the number of hospitalizations and the number of health-insured patients with COPD. 
Increase in the number of health insured let to the increase in the hospitalizations 
resource utilization and cost to determine whether functional decline is associated 
with increased healthcare resource utilization and costs. MethOds: Medicare and 
commercial patients who received an endothelin-receptor antagonist (ERA), phospho-
diesterase type 5 inhibitor (PDE5) or prostacyclin (PG12) and reported a medical claim 
with an ICD-9-CM of 416.0, 416.8 or 416.9 or a medical claim indicating right heart 
catheterization (RHC) were identified from pharmacy and medical claims data from 
2009 through 2013. The date of initial therapy served as the index date. Using provider-
reported data from prior authorization forms required for prescribing advanced PAH 
therapies listed above, the WHO-FC was found for 437 patients (FCII= 99; FCIII= 282; 
FCIV= 56). Results: Linear models indicated that the FCIV cohort averaged signifi-
cantly more inpatient admissions (Ps< 0.001), longer lengths of stay (Ps< 0.01) and 
more ER visits (Ps< 0.01) than the FCII or FCIII cohorts. Costs analyses indicated that 
FCIV had significantly higher medical costs than FCII ($130,572/year vs $120,588/year) 
(P= 0.002) and significantly higher total costs (pharmacy + medical) ($180,828/year vs 
$162,072/year) (P= 0.004). cOnclusiOns: PAH patients demonstrated a high level of 
utilization and costs. Disease severity, indicated by WHO-FC, is associated with higher 
utilization and costs for FCIV patients. Only small differences were found between 
FCII and FCIII. The FCIII cohort was twice as large as the FCII cohort. This suggests 
difficulty differentiating between these two FCs and potential bias in the sampling 
when relying on the prior authorization form for this clinical information.
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BURdEn of SymPtomatiC CoPd PatiEntS in SPain: data fRom 
ContinUing to ConfRont CoPd intERnational PatiEnt SURvEy 2012-
2013
Huerta A1, Landis SH2, Punekar YS3
1GlaxoSmithKline, Tres Cantos (Madrid), Spain, 2GlaxoSmithKline, Uxbridge, Middlesex, UK, 
3GlaxoSmithKline, Uxbridge, UK
Objectives: The Continuing to Confront COPD International Patient Survey 
estimated the prevalence and burden of chronic obstructive pulmonary disease 
(COPD) across 12 countries. The objective of this sub-study was to estimate the 
humanistic and economic burden associated with dyspnoea in Spanish patients 
with COPD. MethOds: Spanish COPD patients from a cross-sectional population-
based survey conducted between November 2012 and May 2013, including subjects 
> 40 years fulfilling a case-definition of COPD based on a self-reported physician 
diagnosis or symptomatology were included. Patients were further classified as no/
mild dyspnoea (mMRC < 2) and moderate/severe dyspnoea (mMRC > 2), according 
to modified Medical Council Scale (mMRC) score. Impact of dyspnoea on health-
related quality of life (QoL) measured with COPD Assessment Test (CAT) and costs 
were compared between the two groups. Direct healthcare costs included moderate 
(community treated) and severe COPD exacerbations (requiring emergency room 
visits and/or hospitalization), primary care visits, COPD treatment including oxygen 
use, and immunization in the previous 12 months. Indirect costs included work loss 
estimated using the Work Productivity and Activity Impairment Scale. Results: 303 
Spanish subjects were included; mean age 65.1 years old, 57% male and 73.6% self-
reported moderate to very severe COPD. 47.1% of the subjects included were classi-
fied as having moderate/severe dyspnoea. These dyspnoeic patients showed a higher 
impact on QoL (CAT score > 20): 57.2% vs 28.8%, as well as higher costs than patients 
reporting no/mild dyspnoea: direct costs: 3,938€ vs 1,818€ (p< 0.001), indirect costs: 
3,596€ vs 3,011€ (p= 0.426), societal costs: 7,534€ vs 4,828€ (p= 0.004). cOnclusiOns: 
The frequency of moderate/severe dyspnoea is high among Spanish COPD patients. 
Dysponea was associated with higher impact on QoL and higher societal costs. 
Healthcare strategies targeted to improve dyspnoea symptoms could reduce the 
burden associated with COPD.
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CoSt of Smoking in aSia
Lee VW, Leung RS, Li A, Ng E
The Chinese University of Hong Kong, Shatin, Hong Kong
Objectives: The current project aims to (1) evaluate cost burden of smoking to Asia 
and (2) increase public awareness on smoking and its clinical and economic impact 
to the society. MethOds: This is a retrospective literature review aiming to inves-
tigate the published work related to the burden of smoking to smokers since 2000. 
All published articles related to cost of smoking were reviewed. The current costs 
of each pack of cigarettes in the target Asia-Pacific countries (Hong Kong, Malaysia, 
Thailand, Philippines, South Korea, Singapore and Australia) were documented. Both 
tobacco cost per smoker (out-of-pocket) and the direct health care cost per smoker 
were estimated. The prevalence of smokers in each country was documented and 
for the calculation of the out-of-pocket cost per each smoker based on published 
data. The direct health care expenditure was documented based on the published 
data. We also estimated the cost of saving if the smoker stops smoking accord-
ing to the specific age and the expected life expectancy in each country. All cost 
estimation was based on the year 2014. Results: In 2014, the estimated annual 
government expenditure on managing smoking related diseases was Hong Kong 
(USD 1.45 billion), Malaysia (USD 1.11 billion), Thailand (USD 8.48 billion), Philippines 
(USD 7.70 billion), South Korea (USD 1.61 billion), Singapore (USD 0.72 billion) and 
Australia (USD 1.69 billion). Among the 7 countries, the smokers spend the most 
in Australia, Singapore and Hong Kong. The annual out-of-pocket cost for smokers 
for one pack per day was Hong Kong (USD 2620), Malaysia (USD 1460), Thailand 
(USD 1095), Philippines (USD 511), South Korea (USD 1825), Singapore (USD 3650) 
and Australia (USD 6935). cOnclusiOns: The cost burden of smoking is high from 
both smokers and government perspectives. Reduction of the smoking population 
can significantly alleviate the disease burden and reduce public health expenditure.
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Examining hEalth SyStEm and RESoURCE Utilization and mEdiCal 
managEmEnt of PatiEntS idioPathiC PUlmonaRy fiBRoSiS in ontaRio: a 
PREliminaRy analySiS
Mittmann N1, Hassan S1, Seung SJ1, Saherawala H1, Hoffstein V2, Bradley-Kennedy C3
